Woman's World on MSN

Blood in your urine? 5 bladder cancer symptoms you should never ignore

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being ...
Daily Excelsior

AIIMS Jammu launches advanced endourological procedures

Department of Urology, All India Institute of Medical Sciences (AIIMS) Jammu, has commenced advanced endourological services, ...
MedPage Today

Identifying High-Risk Patients to Reduce Urinary Tract Infections After Bladder Resection

“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...
Nasdaq

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...
Frontiers

Analysis of risk factors for ureteral stricture and tumor recurrence after transurethral resection of bladder tumor in paraureteral bladder cancer

Background: This study explores the risk factors for ureteral stricture and tumor recurrence after transurethral resection of bladder tumor (TURBT) in patients with paraureteral bladder cancer, aiming ...
Business Insider

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle ...

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...
Cure Today

What to Know About Early-Stage Urothelial Carcinoma

Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...
Seeking Alpha

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE ...
MedPage Today

New Treatment Options for Non-Muscle-Invasive Bladder Cancer

or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...
Seeking Alpha

U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...
urologytimes

En bloc resection of bladder tumor: Is it the way forward?

TURBT's piecemeal approach risks tumor cell reimplantation and lacks precise margin assessment, challenging oncological principles. ERBT, facilitated by advanced imaging and technology, allows for en ...
emjreviews.com

AI System for Detecting Flat Bladder Tumours in Cystoscopic Images

Olympus Corporation supported the following instruments to conduct this research (CLV-S400, OTV-S400, WM-NP2, LMD-X310S, HVO-4000ST, WA2TA430A, WA03200A, CH-S400-XZ-EB, WA05990A). The authors ...